全文获取类型
收费全文 | 256篇 |
免费 | 17篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 1篇 |
妇产科学 | 1篇 |
基础医学 | 16篇 |
口腔科学 | 1篇 |
临床医学 | 5篇 |
内科学 | 25篇 |
皮肤病学 | 2篇 |
神经病学 | 74篇 |
特种医学 | 4篇 |
外科学 | 53篇 |
预防医学 | 7篇 |
肿瘤学 | 80篇 |
出版年
2023年 | 1篇 |
2022年 | 4篇 |
2021年 | 8篇 |
2020年 | 6篇 |
2019年 | 5篇 |
2018年 | 4篇 |
2017年 | 4篇 |
2016年 | 3篇 |
2015年 | 8篇 |
2014年 | 10篇 |
2013年 | 9篇 |
2012年 | 12篇 |
2011年 | 9篇 |
2010年 | 8篇 |
2009年 | 3篇 |
2008年 | 10篇 |
2007年 | 7篇 |
2006年 | 11篇 |
2005年 | 10篇 |
2004年 | 13篇 |
2003年 | 10篇 |
2002年 | 9篇 |
2001年 | 11篇 |
2000年 | 22篇 |
1999年 | 16篇 |
1998年 | 2篇 |
1997年 | 2篇 |
1996年 | 5篇 |
1995年 | 6篇 |
1994年 | 4篇 |
1992年 | 4篇 |
1991年 | 4篇 |
1990年 | 4篇 |
1989年 | 2篇 |
1988年 | 3篇 |
1987年 | 6篇 |
1986年 | 2篇 |
1985年 | 5篇 |
1984年 | 1篇 |
1981年 | 1篇 |
1980年 | 2篇 |
1979年 | 2篇 |
1976年 | 2篇 |
1974年 | 1篇 |
1969年 | 2篇 |
排序方式: 共有273条查询结果,搜索用时 15 毫秒
91.
92.
Masahiro Sonoo 《Clinical neurology》2002,42(1):54; author reply 55-54; author reply 56
93.
Renal involvement in POEMS syndrome 总被引:3,自引:0,他引:3
S Mizuiri K Mitsuo K Sakai I Hayashi T Suzuki Y Nagai T Ohara A Hasegawa S Kawamura 《Nephron》1991,59(1):153-156
We describe a patient with POEMS syndrome whose renal biopsy specimen also showed nephropathy. Immunoelectron microscopy of the renal biopsy revealed the localization of immunoglobulin (IgA and lambda light chain) in the subendothelial space of the glomerular capillaries, a previously unrecognized finding. We conclude that the renal pathology in POEMS syndrome is unusual and distinct from microangiopathic glomerular involvement or idiopathic mesangiocapillary glomerulonephritis. 相似文献
94.
95.
96.
Bhutada Abhishek S. Cai Chang Mizuiri Danielle Findlay Anne Chen Jessie Tay Ashley Kirsch Heidi E. Nagarajan Srikantan S. 《Brain topography》2022,35(1):96-107
Brain Topography - Magnetoencephalography (MEG) is a robust method for non-invasive functional brain mapping of sensory cortices due to its exceptional spatial and temporal resolution. The clinical... 相似文献
97.
98.
Tanaka K Hara S Kushiyama A Ubara Y Yoshida Y Mizuiri S Aikawa A Kawatzu S 《Clinical and experimental nephrology》2011,15(3):391-397
Background
Although a high prevalence of macrovascular disease (MVD) has been reported in patients with stage 3 chronic kidney disease (CKD), few studies have reported its risk with respect to the underlying cause of kidney disease. This study investigated the prevalence of MVD in type 2 diabetic patients with CKD stratified by CKD stage, as defined by estimated glomerular filtration rate (eGFR), as well as the risk factors for MVD. 相似文献99.
Toshiro Shimo Junichi Kurebayashi Naoki Kanomata Tetsumasa Yamashita Yuji Kozuka Takuya Moriya Hiroshi Sonoo 《Breast cancer (Tokyo, Japan)》2014,21(1):75-85
Background
Although the poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor olaparib is known to have potent antitumor activity in BRCA-related breast cancer cells, a limited number of preclinical and clinical studies have shown antitumor activity of olaparib in non-BRCA-related breast cancer. We investigated antitumor activity of olaparib in breast cancer cell lines derived from patients with nonfamilial sporadic breast cancer.Methods
Effects of olaparib alone or in combination with five different chemotherapeutic agents on cell growth, cell cycle progression, apoptosis, and proportion of cancer stem cells using the mammosphere assay and CD44/CD24/ESA cell surface marker assay were investigated in a panel of six sporadic breast cancer cell lines. Extracellular-signal-regulated kinase (ERK) phosphorylation was also investigated to elucidate action mechanisms of olaparib.Results
Olaparib inhibited the growth of two estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer cell lines and two ER-negative and HER2-negative breast cancer cell lines (50 % growth inhibitory concentrations 1.3–3.0 μM) associated with G2/M accumulation and induction of apoptosis. In contrast, two HER2-positive cell lines were resistant to olaparib. Interestingly, olaparib significantly decreased the proportion of putative cancer stem cells in either sensitive or resistant cell lines. In addition, olaparib increased expression of p-ERK. Combined treatments of olaparib with a mitogen-activated protein kinase kinase (MEK) inhibitor U0126 completely suppressed expression of p-ERK. These treatments also inhibited the G2/M accumulation and apoptosis induction by olaparib. Among five chemotherapeutic agents commonly used for breast cancer treatment, only an irinotecan metabolite SN38 showed additive antitumor activity with olaparib. Importantly, the combined treatment enhanced the increase in G2/M accumulation and apoptosis induction as well as a decrease in the proportion of cancer stem cells.Conclusions
This study has indicated for the first time that the PARP inhibitor olaparib has substantial antitumor and anticancer stem cell activity in breast cancer cell lines of nonfamilial origin. Upregulation of p-ERK might explain, at least in part, antitumor and anticancer stem cell activity of olaparib. Combined treatment of olaparib with irinotecan might be effective in treatment of non-BRCA-related breast cancer. 相似文献100.
Junichi Kurebayashi Naoki Kanomata Toshiro Shimo Tetsumasa Yamashita Kenjiro Aogi Rieko Nishimura Chikako Shimizu Hitoshi Tsuda Takuya Moriya Hiroshi Sonoo 《Breast cancer (Tokyo, Japan)》2014,21(2):214-222